Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4422 Target Snapshot

Free fatty acid receptor 1 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
3,068Compounds
428Assays
1Approved Drugs
3,847.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Free fatty acid receptor 1 shows late clinical disease relevance led by type 2 diabetes mellitus. 3 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt O14842. Start with type 2 diabetes mellitus, then reuse UniProt O14842 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with type 2 diabetes mellitus, then reuse UniProt O14842 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 2 linked drugs
Open source guide
Disease program
type 2 diabetes mellitus

Free fatty acid receptor 1 shows late clinical disease relevance led by type 2 diabetes mellitus. 3 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.

Start review with type 2 diabetes mellitus because it currently carries late clinical support. Linked drugs include FASIGLIFAM, LY2881835. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Late clinical Open Targets-ready proxy 2 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Free fatty acid receptor 1 as ChEMBL target CHEMBL4422, mapped to UniProt O14842. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Free fatty acid receptor 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4422
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
O14842
Free fatty acid receptor 1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Free fatty acid receptor 1 is the right protein anchor across sources, using UniProt O14842 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why type 2 diabetes mellitus is currently framed as late clinical support. It currently carries 2 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameFree fatty acid receptor 1
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtO14842
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelFree fatty acid receptor 1
UniProt AccessionO14842
Component TypeProtein
Sequence Length300 aa

Free fatty acid receptor 1

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Free fatty acid receptor 1, mapped to UniProt O14842. Sequence length is 300 aa.

Mapped IDO14842
Review nameFree fatty acid receptor 1
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

Free fatty acid receptor 1 shows late clinical disease relevance led by type 2 diabetes mellitus. 3 more disease programs remain visible in the same review block.

Late clinical Phase III
type 2 diabetes mellitus
2 linked drugs · 2 direct · 2 efficacy
Linked drugFASIGLIFAM
Linked drugLY2881835
Late clinical Phase III
diabetes mellitus
1 linked drug · 1 direct · 1 efficacy
Linked drugFASIGLIFAM
Clinical signal Phase II
Alstrom syndrome
1 linked drug · 1 direct · 1 efficacy
Linked drugSETOGEPRAM
Clinical signal Phase I
Hyperammonemia
1 linked drug · 1 direct · 1 efficacy
Linked drugSETOGEPRAM
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with type 2 diabetes mellitus because it currently carries late clinical support. Linked drugs include FASIGLIFAM, LY2881835. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasetype 2 diabetes mellitus
Strongest levelLate clinical
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

1
Approved
5
Phase III
2
Phase II
4
Phase I
Assay Mix

Activity Type Distribution

IC50107.0
KI185.0
EC503,541.0
KD14.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4859651 10.4 EC50 0.04 Preclinical
CHEMBL475027 10.0 EC50 0.1 Preclinical
CHEMBL4541658 9.96 EC50 0.11 Preclinical
CHEMBL4463571 9.7 EC50 0.2 Preclinical
CHEMBL6063201 9.7 EC50 0.2 Preclinical
CHEMBL4457303 9.6 EC50 0.25 Preclinical
CHEMBL4854804 9.6 EC50 0.25 Preclinical
CHEMBL3944424 9.52 EC50 0.3 Preclinical
CHEMBL1829174 9.46 EC50 0.35 Clinical
CHEMBL4848974 9.42 EC50 0.38 Preclinical
Distribution

pChEMBL Value Distribution

249
5.0
315
5.5
451
6.0
538
6.5
601
7.0
596
7.5
334
8.0
90
8.5
22
9.0
7
9.5
pChEMBL
Assay Landscape

Assay Landscape

428
Total Assays
1,563
Tested Compounds
2
Assay Types
Functional — 306 assays, 1,563 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 278 1,408 6.7
assay format 21 136 6.5
single protein format 7 19 5.6
Binding — 122 assays, 1,122 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 80 525 6.7
single protein format 23 85 6.6
assay format 12 473 7.6
cell membrane format 5 39 7.8
tissue-based format 2 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine